Ospemifene plus fractional CO2 laser: a powerful strategy to treat postmenopausal vulvar pain
暂无分享,去创建一个
I. Cetin | F. Murina | R. Felice | S. Di Francesco | S. D. Francesco | L. Nelvastellio | Irene Cetin
[1] I. Goldstein,et al. Improvements to the Vulva, Vestibule, Urethral Meatus, and Vagina in Women Treated With Ospemifene for Moderate to Severe Dyspareunia: A Prospective Vulvoscopic Pilot Study , 2018, Sexual medicine.
[2] F. Murina,et al. Vulvar vestibular effects of ospemifene: a pilot study , 2018, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.
[3] S. Faubion,et al. Genitourinary Syndrome of Menopause: Management Strategies for the Clinician , 2017, Mayo Clinic proceedings.
[4] M. Falagas,et al. CO2-laser for the genitourinary syndrome of menopause. How many laser sessions? , 2017, Maturitas.
[5] J. Manson,et al. The 2017 hormone therapy position statement of The North American Menopause Society , 2017, Menopause.
[6] A. Graziottin,et al. Vulvar Pain: From Childhood to Old Age , 2017 .
[7] S. Salvatore,et al. Fractional CO2 Laser Treatment of the Vestibule for Patients with Vestibulodynia and Genitourinary Syndrome of Menopause: A Pilot Study. , 2016, The journal of sexual medicine.
[8] A. Stavros,et al. The use of pulsed CO2 lasers for the treatment of vulvovaginal atrophy , 2015 .
[9] A. Lev-Sagie. Vulvar and Vaginal Atrophy: Physiology, Clinical Presentation, and Treatment Considerations. , 2015, Clinical obstetrics and gynecology.
[10] N. Biglia,et al. Characteristics of post-menopausal women with genitourinary syndrome of menopause: Implications for vulvovaginal atrophy diagnosis and treatment selection. , 2015, Maturitas.
[11] C. Castelo-Branco,et al. The clinical relevance of the effect of ospemifene on symptoms of vulvar and vaginal atrophy , 2014, Climacteric : the journal of the International Menopause Society.
[12] M. Candiani,et al. The use of pulsed CO2 lasers for the treatment of vulvovaginal atrophy. , 2015, Current opinion in obstetrics & gynecology.
[13] D. Portman,et al. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women’s Sexual Health and The North American Menopause Society , 2014, Menopause.
[14] R. Nappi,et al. Ospemifene, a non-oestrogen selective oestrogen receptor modulator for the treatment of vaginal dryness associated with postmenopausal vulvar and vaginal atrophy: a randomised, placebo-controlled, phase III trial. , 2014, Maturitas.
[15] C. Domoney. Treatment of Vaginal Atrophy , 2014, Women's health.
[16] J. Simon,et al. Long-term safety of ospemifene (52-week extension) in the treatment of vulvar and vaginal atrophy in hysterectomized postmenopausal women. , 2014, Maturitas.
[17] C. Gracia. Practice Bulletin No. 141: Management of Menopausal Symptoms , 2014, Obstetrics and gynecology.
[18] J. Simon,et al. Impact of vulvovaginal health on postmenopausal women: a review of surveys on symptoms of vulvovaginal atrophy , 2013, International journal of women's health.
[19] R. Nappi,et al. Vaginal Health: Insights, Views & Attitudes (VIVA) – results from an international survey , 2012, Climacteric : the journal of the International Menopause Society.
[20] Y. Muscat Baron,et al. Estrogens and the skin , 2005, Climacteric : the journal of the International Menopause Society.
[21] M. Degregorio,et al. In vitro and in vivo biologic effects of Ospemifene (FC-1271a) in breast cancer , 2001, The Journal of Steroid Biochemistry and Molecular Biology.
[22] R. Fitzpatrick,et al. Collagen tightening induced by carbon dioxide laser versus erbium:YAG laser , 2000, Lasers in surgery and medicine.